Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?

Autor:	Nicholls SJ; Victorian Heart Institute, Monash University, Melbourne, Australia., Tan S; Victorian Heart Institute, Monash University, Melbourne, Australia., Butters J; Victorian Heart Institute, Monash University, Melbourne, Australia., Nelson AJ; Victorian Heart Institute, Monash University, Melbourne, Australia.
Jazyk:	angličtina
Zdroj:	Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2024 Oct; Vol. 25 (14), pp. 1879-1885. Date of Electronic Publication: 2024 Sep 27.
DOI:	10.1080/14656566.2024.2409324
Abstrakt:	Introduction: Cholesteryl ester transfer protein (CETP) plays an important role in lipid metabolism. Early interest in the development of CETP inhibitors proved to be disappointing. Recent interest has focused on the potential for CETP inhibition to reduce cardiovascular risk by lowering levels of low-density lipoprotein cholesterol (LDL-C). Areas Covered: The data suggesting that low CETP activity may associate with lower levels of cardiovascular risk and early experience with CETP inhibitors focused on raising HDL-C levels. More recent data that suggests that any potential to reduce cardiovascular risk by inhibition of CETP is more likely to result from lowering levels of atherogenic lipid parameters. The development of obicetrapib, a potent CETP inhibitor, with robust lowering of apoB and LDL-C, will be summarized as a potential approach to the prevention of cardiovascular disease. Expert Opinion: Obicetrapib is a potent CETP inhibitor, with a demonstrated ability to lower levels of apoB and LDL-C as monotherapy and in addition to high intensity statin therapy. The ultimate impact of obicetrapib on cardiovascular events will be evaluated by ongoing clinical trials.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu